Les thérapies ciblées de l'os métastatique: soins de support ou traitements de fond?

L. Albiges; C. Massard; Y. Loriot; K. Fizazi

doi:10.1007/s10269-012-2121-5

Les thérapies ciblées de l'os métastatique: soins de support ou traitements de fond?

L. Albiges, C. Massard, Y. Loriot, K. Fizazi

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

Résumé

Bone metastases in prostate cancer treatment stand as a clinical challenge in order to maintain quality of life and prevent pain and skeletal-related events. Bone metastases predominantly disrupts the dynamic equilibrium existing in healthy bone between osteogenesis and osteolysis. Therefore, bone microenvironment targeting agents under development are emerging as a specific component of care in the treatment of patients with metastatic prostate cancer.

Titre traduit de la contribution	Targeted therapy to the bone in castration resistant prostate cancer
langue originale	Français
Pages (de - à)	103-107
Nombre de pages	5
journal	Oncologie
Volume	14
Numéro de publication	2
Les DOIs	https://doi.org/10.1007/s10269-012-2121-5
état	Publié - 1 févr. 2012

mots-clés

Bisphosphonates
Bone metastases
RANKL
SRAE

Accès au document

10.1007/s10269-012-2121-5

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{838d6ee212c44b50be80c36c8e956587,

title = "Les th{\'e}rapies cibl{\'e}es de l'os m{\'e}tastatique: soins de support ou traitements de fond?",

abstract = "Bone metastases in prostate cancer treatment stand as a clinical challenge in order to maintain quality of life and prevent pain and skeletal-related events. Bone metastases predominantly disrupts the dynamic equilibrium existing in healthy bone between osteogenesis and osteolysis. Therefore, bone microenvironment targeting agents under development are emerging as a specific component of care in the treatment of patients with metastatic prostate cancer.",

keywords = "Bisphosphonates, Bone metastases, RANKL, SRAE",

author = "L. Albiges and C. Massard and Y. Loriot and K. Fizazi",

year = "2012",

month = feb,

day = "1",

doi = "10.1007/s10269-012-2121-5",

language = "Fran{\c c}ais",

volume = "14",

pages = "103--107",

journal = "Oncologie",

issn = "1292-3818",

number = "2",

}

TY - JOUR

T1 - Les thérapies ciblées de l'os métastatique

T2 - soins de support ou traitements de fond?

AU - Albiges, L.

AU - Massard, C.

AU - Loriot, Y.

AU - Fizazi, K.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Bone metastases in prostate cancer treatment stand as a clinical challenge in order to maintain quality of life and prevent pain and skeletal-related events. Bone metastases predominantly disrupts the dynamic equilibrium existing in healthy bone between osteogenesis and osteolysis. Therefore, bone microenvironment targeting agents under development are emerging as a specific component of care in the treatment of patients with metastatic prostate cancer.

AB - Bone metastases in prostate cancer treatment stand as a clinical challenge in order to maintain quality of life and prevent pain and skeletal-related events. Bone metastases predominantly disrupts the dynamic equilibrium existing in healthy bone between osteogenesis and osteolysis. Therefore, bone microenvironment targeting agents under development are emerging as a specific component of care in the treatment of patients with metastatic prostate cancer.

KW - Bisphosphonates

KW - Bone metastases

KW - RANKL

KW - SRAE

UR - http://www.scopus.com/inward/record.url?scp=84861887411&partnerID=8YFLogxK

U2 - 10.1007/s10269-012-2121-5

DO - 10.1007/s10269-012-2121-5

M3 - Article

AN - SCOPUS:84861887411

SN - 1292-3818

VL - 14

SP - 103

EP - 107

JO - Oncologie

JF - Oncologie

IS - 2

ER -